Skip to main content
Saniona logo

Saniona — Investor Relations & Filings

Ticker · SANION ISIN · SE0005794617 LEI · 549300XO4L9XNOCFCZ84 ST Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2022-05-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SANION

About Saniona

http://saniona.com

Saniona is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurological disorders, with a primary emphasis on epilepsy. The company is a leader in the field of ion channel modulation, leveraging its expertise and a proprietary drug discovery engine to create new medicines. Saniona has developed an extensive library of over 20,000 proprietary molecules designed to target various ion channels. Its pipeline includes multiple potential new medicines advancing through clinical trials, with the goal of addressing unmet medical needs for patients with central nervous system diseases.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT FOR SANIONA AB (PUBL) January - March 2022'. It contains comprehensive financial data, including revenue, operating loss, net loss, and loss per share for the Q1 period. It also includes management commentary, business highlights, and a detailed clinical pipeline overview. As it provides substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2022
2022-05-25 English
Saniona uppdaterar om pågående granskning av tesofensin i Mexiko
Regulatory Filings Classification · 95% confidence The document is a press release from Saniona regarding a regulatory update from the Mexican health authority (COFEPRIS) concerning the drug candidate tesofensin. It details a specific regulatory event/outcome rather than a financial report, dividend, or management change. As it is a general regulatory announcement that does not fit into more specific categories like M&A or legal proceedings (it is a status update on a regulatory review process), it falls under the RNS (Regulatory Filings) category.
2022-05-20 Swedish
Saniona provides update on ongoing review of tesofensine in Mexico
Regulatory Filings Classification · 95% confidence The document is a press release from Saniona regarding a regulatory update from COFEPRIS in Mexico concerning their drug candidate, tesofensine. It does not fit into specific categories like financial reports, board changes, or shareholder voting. As it is a general regulatory announcement regarding company operations and regulatory status, it falls under the RNS (Regulatory Filings) category.
2022-05-20 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding by Avanza Bank Holding AB in Saniona AB, specifically crossing the 5% threshold. This is a classic major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2022-05-02 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 100% confidence FY 2021
2022-04-30 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a 'flaggningsmeddelande' (flagging notification). It details a change in shareholding by RA Capital Management LP in Saniona AB, specifically noting a sale that reduced their stake below a 10% threshold. This falls under the definition of a Major Shareholding Notification (MRQ).
2022-04-29 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.